ChinaDaily Briefs

Daily Brief China: SHEIN, WuXi AppTec, 4Paradigm, Alibaba Group Holding , BYD, China Railway Signal & Communication, Ascentage Pharma Group Corp, Fangzhou, Iron Ore, China Vanke and more

In today’s briefing:

  • Growth of SHEIN, Temu Appears to Be Boosting Asia-US Air Cargo Volume & Pricing
  • China Healthcare Weekly (Jun16)-WuXi Get A “Reprieve”, Vaccine Company in Trouble, Insurance Surplus
  • 4Paradigm: Sage AI Platform 5.0. Could Drive ~30% Y/Y Revenue Growth in 2024, PT Raised To HK$100
  • ECM Weekly (17th June 2024)-Shift Up, Webtoon, Quantum, Guzman, MaoGeping, Johor Plant, Telix, Atour
  • China Consumption Weekly (17 Jun 2024): BYD, Geely, Zeekr, Zhihu, China Literature, Tencent
  • China CRSC (3969 HK): Well Worth the Premium
  • Ascentage Pharma (6855.HK) Signs $1.3B Deal with Takeda – Finally on the Right Path
  • Pre-IPO Fangzhou Inc. (PHIP Updates) – Some Points Worth the Attention
  • Harvesting Seasonality in Iron Ore Prices Induced by Weather, Inventory Restocking, and Holidays
  • Morning Views Asia: Bharti Airtel, China Vanke , Nickel Industries


Growth of SHEIN, Temu Appears to Be Boosting Asia-US Air Cargo Volume & Pricing

By Daniel Hellberg

  • For first time since 2022, carriers’ cargo revenue, yield, load factor all rising
  • Asia outbound, US inbound air cargo tons both improving in early 2024
  • SHEIN, Temu could account for 40%+ of US inbound air tons from CH, HK, TW

China Healthcare Weekly (Jun16)-WuXi Get A “Reprieve”, Vaccine Company in Trouble, Insurance Surplus

By Xinyao (Criss) Wang

  • Due to increasing competition/price reduction/overcapacity issue, outlook of domestic vaccine companies isn’t optimistic, which has been reflected in 24Q1 results. However, there’s also a “special one” that deserves investors’ attention.
  • The status of medical insurance funds is improving rather than deteriorating, but we’re currently in the first half of the decade with the highest pressure on medical insurance.
  • As the H.R.8333 proposal faced obstacles in the process of being included in NDAA, WuXi AppTec/WuXi Bio’s shares once rebounded.We remain conservative as situation is not as simple as imagined.

4Paradigm: Sage AI Platform 5.0. Could Drive ~30% Y/Y Revenue Growth in 2024, PT Raised To HK$100

By Andrei Zakharov

  • 4Paradigm, China’s AI software company with focus on enterprise-level solutions, performed well and achieved solid growth in 2023 and Q1 2024. 
  • In my insight, I discuss valuation framework for comparable company analysis and set a new 12-month PT for 4Paradigm.
  • The company’s management has set a clear goal of profitability. I like 4Paradigm’s leadership position and hyper-growth in revenue from the Sage AI Platform.

ECM Weekly (17th June 2024)-Shift Up, Webtoon, Quantum, Guzman, MaoGeping, Johor Plant, Telix, Atour

By Sumeet Singh


China Consumption Weekly (17 Jun 2024): BYD, Geely, Zeekr, Zhihu, China Literature, Tencent

By Ming Lu

  • European Commission will impose provisional tariffs on imported Chinese battery electric vehicles.
  • Zeekr’s deliveries increased by 117% YoY in 1Q24 and by 112% YoY in the first five months of 2024.
  • Ant Group will pay RMB1 billion to sponsor content creators on AliPay.

China CRSC (3969 HK): Well Worth the Premium

By Osbert Tang, CFA

  • China Railway Signal & Communication (3969 HK)‘s latest order backlog is estimated to be Rmb173.7bn, enough to cover FY24F revenue by 4.4x.
  • Gross margin has sustained expansion, reaching a record high of 27.8% in 1Q24. Higher R&D expenses will benefit its medium-term earnings.
  • Net cash equals 59% of the share price, allowing it to maintain over 50% payout and potentially higher going forward. Operating cash flow has also turned around to positive.

Ascentage Pharma (6855.HK) Signs $1.3B Deal with Takeda – Finally on the Right Path

By Xinyao (Criss) Wang

  • Ascentage was originally in an extremely difficult situation, but the cooperation with Takeda turned things around. Ascentage has obtained urgently needed cash flow to solve the survival problem.
  • At this stage, it’s possible for Ascentage to hit about 50% market value of HCM.  Investors are interested to know if APG-2575 would also be out-licensed, which however is not easy.
  • Ascentage’s current strength isn’t sufficient to self-build sales system. While this deal is a good start, if Ascentage still chooses to do commercialization on its own, it’s time to sell. 

Pre-IPO Fangzhou Inc. (PHIP Updates) – Some Points Worth the Attention

By Xinyao (Criss) Wang

  • Fangzhou cannot get around the decreasing unit-price of drugs and the increasing role of medical insurance in chronic-disease treatment.It’s challenging to find patients willing to pay out of own pockets.
  • The internal dispute between the Founder and shareholders hasn’t ended, and related litigation is still pending. This makes us concerned about the stability of future business development and corporate governance. 
  • Fangzhou has significant cash flow pressure. In the case of increasingly fierce competition in the industry, without successful business diversification/transformation, growth prospects is gloomy, Valuation should be lower than peers. 

Harvesting Seasonality in Iron Ore Prices Induced by Weather, Inventory Restocking, and Holidays

By Srinidhi Raghavendra

  • SGX Iron Ore prices exhibit seasonality. For select six months being long Iron Ore combined with short positions during other months deliver positive P&L based on back tests. 
  • In line with prices, realised volatility exhibits seasonality too. Options strategies can exploit this to deliver superior alpha & higher sharpe ratio.
  • Averages confound extreme variances. Monthly iron ore futures price returns are less volatile during the months of December, February, June, October, & March based on range.

Morning Views Asia: Bharti Airtel, China Vanke , Nickel Industries

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars